Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144247 · ClinicalTrials.gov registry record · Phase 1
Cellular Immunotherapy Study for Brain Cancer
A Phase 1 study of Glioblastoma Multiforme and Anaplastic Astrocytoma, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01144247: Completed Phase 1 study of Glioblastoma Multiforme and Anaplastic Astrocytoma, sponsored by Jonsson Comprehensive Cancer Center.
NCT01144247 is a Phase 1 study of Glioblastoma Multiforme and Anaplastic Astrocytoma that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 10 participants, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01144247, a Phase 1 study of Glioblastoma Multiforme and Anaplastic Astrocytoma, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study to determine if treating recurrent malignant gliomas with another person's (donor) immune system cells known as aCTL cells, will be safe. This study will also try to determine if persons who receive aCTL's are more or less likely to survive their brain tumor than persons who had similar tumors in the past. Approximately 15 patients will be enrolled at UCLA.
Conditions Studied
Interventions
- DRUG alloreactive CTL
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
What the finished NCT01144247 record still lists
NCT01144247 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (90% lower).
The record links to 6 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which alloreactive CTL is the first listed.
NCT01144247 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01144247 about?
NCT01144247 is a clinical study titled "Cellular Immunotherapy Study for Brain Cancer". The purpose of this research study to determine if treating recurrent malignant gliomas with another person's (donor) immune system cells known as aCTL cells, will be safe. This study will also try to determine if persons who receive aCTL's are more or less likely to survive their brain tumor than p...
What is the current status of trial NCT01144247?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2010-07. Estimated completion is 2015-07.
What conditions does trial NCT01144247 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Gliomas, Anaplastic Mixed Glioma.
What interventions are being tested in trial NCT01144247?
The interventions under investigation include: alloreactive CTL (DRUG).
Who is sponsoring clinical trial NCT01144247?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01144247 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01144247's enrollment target sits among peer trials
10 82nd of 88 higher than 4 of 88 other Glioblastoma Multiforme trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma Multiforme trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia